-
公开(公告)号:US20070155761A1
公开(公告)日:2007-07-05
申请号:US11640739
申请日:2006-12-18
申请人: Caterina Bissantz , Christophe Grundschober , Hasane Ratni , Mark Rogers-Evans , Patrick Schnider
发明人: Caterina Bissantz , Christophe Grundschober , Hasane Ratni , Mark Rogers-Evans , Patrick Schnider
IPC分类号: A61K31/519 , A61K31/4747 , C07D487/10 , C07D471/10
CPC分类号: C07D471/10
摘要: This invention relates to indol-3-yl-carbonyl-spiro-piperidine derivatives which act as Via receptor antagonists and which are represented by Formula I: wherein the spiropiperidine-head group A and the residues R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, their use in the treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders, and to methods of preparation thereof.
摘要翻译: 本发明涉及作为Via受体拮抗剂并由式I表示的吲哚-3-基 - 羰基 - 螺 - 哌啶衍生物:其中spiropiperidine-head基团A和残基R 1, R 2和R 3如本文所定义。 本发明还涉及含有这些化合物的药物组合物,它们在治疗痛经,高血压,慢性心力衰竭,不适当的血管加压素分泌,肝硬化,肾病综合征,强迫症,焦虑和抑郁障碍中的应用,以及制备方法 其中。
-
公开(公告)号:US20070072888A1
公开(公告)日:2007-03-29
申请号:US11524978
申请日:2006-09-21
申请人: Caterina Bissantz , Christophe Grundschober , Hasane Ratni , Mark Rogers-Evans , Patrick Schnider
发明人: Caterina Bissantz , Christophe Grundschober , Hasane Ratni , Mark Rogers-Evans , Patrick Schnider
IPC分类号: A61K31/4747 , C07D491/10 , C07D487/10
CPC分类号: C07D471/10 , C07D491/10
摘要: This invention relates to indol-3-yl-carbonyl-azaspiro derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the azaspiro-head group A and the residues R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, their use for treating dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders, and methods of preparation thereof.
摘要翻译: 本发明涉及作为V1a受体拮抗剂并由式I表示的吲哚-3-基 - 羰基 - 氮杂螺环衍生物:其中azaspiro-head基团A和残基R 1, SUP> 2>和R 3>如本文所定义。 本发明还涉及含有这些化合物的药物组合物,其用于治疗痛经,高血压,慢性心力衰竭,不适当的血管加压素分泌,肝硬化,肾病综合征,强迫症,焦虑和抑郁障碍的用途及其制备方法。
-
公开(公告)号:US20070027163A1
公开(公告)日:2007-02-01
申请号:US11492312
申请日:2006-07-25
申请人: Caterina Bissantz , Christophe Grundschober , Hasane Ratni , Mark Rogers-Evans , Patrick Schnider
发明人: Caterina Bissantz , Christophe Grundschober , Hasane Ratni , Mark Rogers-Evans , Patrick Schnider
IPC分类号: A61K31/496 , A61K31/454 , A61K31/4439 , C07D403/02
CPC分类号: C07D209/42 , C07D209/22 , C07D401/06 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/12 , C07D405/14 , C07D417/12 , C07D495/04
摘要: The present invention relates to indol-3-yl-carbonyl-piperidin and piperazin derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the residues R1 to R3 are as defined herein. The invention also relates to pharmaceutical compositions containing such compounds, and methods for preparation of the compounds and compositions. The invention further relates to methods for treating dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders.
摘要翻译: 本发明涉及作为V1a受体拮抗剂并由式I表示的吲哚-3-基 - 羰基 - 哌啶和哌嗪衍生物:其中残基R 1至R 3, / SUP>如本文所定义。 本发明还涉及含有这些化合物的药物组合物,以及制备化合物和组合物的方法。 本发明还涉及治疗痛经,高血压,慢性心力衰竭,不适当的血管加压素分泌,肝硬化,肾病综合征,强迫症,焦虑和抑郁障碍的方法。
-
公开(公告)号:US08084609B2
公开(公告)日:2011-12-27
申请号:US11955452
申请日:2007-12-13
申请人: Caterina Bissantz , Christophe Grundschober , Raffaello Masciadri , Hasane Ratni , Mark Rogers-Evans , Patrick Schnider
发明人: Caterina Bissantz , Christophe Grundschober , Raffaello Masciadri , Hasane Ratni , Mark Rogers-Evans , Patrick Schnider
IPC分类号: C07D405/04 , A61K31/438
CPC分类号: C07D491/107 , C07D211/16 , C07D221/20 , C07D401/06 , C07D405/06 , C07D471/10
摘要: The present invention is concerned with novel spiro-piperidine derivatives as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use for the treatment of anxiety and depressive disorders and other diseases. The compounds of present invention are described with formula (I) wherein R1 to R5, R5′, R7 to R9, R7′, R8′, X and Y are as defined in the specification.
摘要翻译: 本发明涉及作为V1a受体拮抗剂的新型螺哌啶衍生物,其制造方法,含有它们的药物组合物及其用于治疗焦虑抑郁障碍和其它疾病的用途。 本发明的化合物用式(I)描述,其中R 1至R 5,R 5',R 7至R 9,R 7',R 8',X和Y如说明书中所定义。
-
公开(公告)号:US08044202B2
公开(公告)日:2011-10-25
申请号:US11960799
申请日:2007-12-20
申请人: Caterina Bissantz , Christophe Grundschober , Raffaello Masciadri , Hasane Ratni , Mark Rogers-Evans , Patrick Schnider
发明人: Caterina Bissantz , Christophe Grundschober , Raffaello Masciadri , Hasane Ratni , Mark Rogers-Evans , Patrick Schnider
IPC分类号: A61K31/438 , C07D401/04
CPC分类号: C07D491/20
摘要: The present invention is concerned with novel indol-3-yl-carbonyl-azaspiropiperidine derivatives as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use for the treatment of anxiety and depressive disorders and other diseases. In particular, the present invention is concerned with compounds of the general formula (I) wherein R1 to R6, U, V, W, X, Y and Z are as defined in the specification.
-
公开(公告)号:US08026259B2
公开(公告)日:2011-09-27
申请号:US11947906
申请日:2007-11-30
申请人: Caterina Bissantz , Christophe Grundschober , Raffaello Masciadri , Hasane Ratni , Mark Rogers-Evans , Patrick Schnider
发明人: Caterina Bissantz , Christophe Grundschober , Raffaello Masciadri , Hasane Ratni , Mark Rogers-Evans , Patrick Schnider
IPC分类号: A61K31/4439 , C07D401/10
CPC分类号: C07D401/04 , C07D413/14
摘要: The present invention is concerned with novel indol-2-yl-carbonyl-piperidine derivatives as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful in the prevention and/or treatment of anxiety and depressive disorders and other diseases. Present invention is concerned with compounds of the general formula (I) wherein R1 to R6, R8 to R14, R12,, R13,, X and Y are as defined in the specification.
摘要翻译: 本发明涉及作为V1a受体拮抗剂的新型吲哚-2-基 - 羰基 - 哌啶衍生物,其制备方法,含有它们的药物组合物及其作为药物的用途。 本发明的活性化合物可用于预防和/或治疗焦虑和抑郁症等疾病。 本发明涉及通式(I)的化合物,其中R 1至R 6,R 8至R 14,R 12,R 13,X和Y如说明书中所定义。
-
公开(公告)号:US07799923B2
公开(公告)日:2010-09-21
申请号:US11998371
申请日:2007-11-29
申请人: Caterina Bissantz , Christophe Grundschober , Raffaello Masciadri , Hasane Ratni , Mark Rogers-Evans , Patrick Schnider
发明人: Caterina Bissantz , Christophe Grundschober , Raffaello Masciadri , Hasane Ratni , Mark Rogers-Evans , Patrick Schnider
IPC分类号: C07D211/32
CPC分类号: C07D401/14 , C07D491/04
摘要: The present invention is concerned with novel indol-2-yl-carbonyl-piperidin-benzoimidazolon and indol-2-yl-carbonyl-piperidin-benzoxazolon derivatives as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use for the treatment of anxiety and depressive disorders and other diseases. In particular, the present invention concerns compounds of formula (I) wherein R1 to R11, X and Y are as defined in the specification.
摘要翻译: 本发明涉及新的吲哚-2-基 - 羰基 - 哌啶 - 苯并咪唑酮和吲哚-2-基 - 羰基 - 哌啶 - 苯并恶唑酮衍生物作为V1a受体拮抗剂,其制备方法,含有它们的药物组合物及其用于治疗 焦虑抑郁障碍等疾病。 特别地,本发明涉及其中R 1至R 11,X和Y如说明书中所定义的式(I)化合物。
-
公开(公告)号:US07790752B2
公开(公告)日:2010-09-07
申请号:US11524978
申请日:2006-09-21
申请人: Caterina Bissantz , Christophe Grundschober , Hasane Ratni , Mark Rogers-Evans , Patrick Schnider
发明人: Caterina Bissantz , Christophe Grundschober , Hasane Ratni , Mark Rogers-Evans , Patrick Schnider
IPC分类号: A61K31/438 , C07D401/14
CPC分类号: C07D471/10 , C07D491/10
摘要: This invention relates to indol-3-yl-carbonyl-azaspiro derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the azaspiro-head group A and the residues R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, their use for treating dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders, and methods of preparation thereof.
摘要翻译: 本发明涉及作为V1a受体拮抗剂并由式I表示的吲哚-3-基 - 羰基 - 氮杂螺环衍生物:其中阿扎头罗头基A和残基R1,R2和R3如本文所定义。 本发明还涉及含有这些化合物的药物组合物,其用于治疗痛经,高血压,慢性心力衰竭,不适当的血管加压素分泌,肝硬化,肾病综合征,强迫症,焦虑和抑郁障碍的用途及其制备方法。
-
公开(公告)号:US07495008B2
公开(公告)日:2009-02-24
申请号:US11955425
申请日:2007-12-13
申请人: Caterina Bissantz , Christophe Grundschober , Raffaello Masciadri , Hasane Ratni , Mark Rogers-Evans , Patrick Schnider
发明人: Caterina Bissantz , Christophe Grundschober , Raffaello Masciadri , Hasane Ratni , Mark Rogers-Evans , Patrick Schnider
IPC分类号: A61K31/438 , C07D491/107
CPC分类号: C07D211/16 , C07D471/10 , C07D491/10 , C07D519/00
摘要: The present invention is concerned with novel spiro-piperidine derivatives as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful in the prevention and/or treatment of anxiety and depressive disorders and other diseases.In particular, the present invention is concerned with compounds of the general formula (I) wherein R1 to R5, R5′, X, Y and A are as defined in the specification.
摘要翻译: 本发明涉及作为V1a受体拮抗剂的新型螺 - 哌啶衍生物,其制备方法,含有它们的药物组合物及其作为药物的用途。 本发明的活性化合物可用于预防和/或治疗焦虑和抑郁症等疾病。 特别地,本发明涉及通式(I)的化合物,其中R 1至R 5,R 5',X,Y和A如说明书中所定义。
-
公开(公告)号:US20080280898A1
公开(公告)日:2008-11-13
申请号:US11955434
申请日:2007-12-13
申请人: Caterina Bissantz , Christophe Grundschober , Raffaello Masciadri , Hasane Ratni , Mark Rogers-Evans , Patrick Schnider
发明人: Caterina Bissantz , Christophe Grundschober , Raffaello Masciadri , Hasane Ratni , Mark Rogers-Evans , Patrick Schnider
IPC分类号: A61K31/438 , C07D401/04 , A61K31/5377 , A61P9/00 , A61P25/00 , C07D265/30
CPC分类号: C07D211/16 , C07D471/10 , C07D491/10 , C07D519/00
摘要: The present invention is concerned with novel spiro-piperidine derivatives as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful in the prevention and/or treatment of anxiety and depressive disorders and other diseases.In particular, the present invention is concerned with compounds of the general formula (I) wherein R1 to R5, R5′, X, Y and A are as defined in the specification.
-
-
-
-
-
-
-
-
-